Research ExplorerPublicationsNo correlation between RET immunostaining and the codon 918 ...

No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma

Standard

No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma. / Bockhorn, M; Frilling, A; Kalinin, V; Schröder, S; Broelsch, C E.

In: LANGENBECK ARCH SURG, Vol. 384, No. 1, 01.02.1999, p. 60-4.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bockhorn, M, Frilling, A, Kalinin, V, Schröder, S & Broelsch, CE 1999, 'No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma', LANGENBECK ARCH SURG, vol. 384, no. 1, pp. 60-4.

APA

Bockhorn, M., Frilling, A., Kalinin, V., Schröder, S., & Broelsch, C. E. (1999). No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma. LANGENBECK ARCH SURG, 384(1), 60-4.

Vancouver

Bockhorn M, Frilling A, Kalinin V, Schröder S, Broelsch CE. No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma. LANGENBECK ARCH SURG. 1999 Feb 1;384(1):60-4.

Bibtex

@article{cbd08231df23411cae01b5c522ca7c42,
title = "No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma",
abstract = "INTRODUCTION: Medullary thyroid carcinoma (MTC) occurs sporadically or as part of the inherited cancer syndrome, multiple endocrine neoplasia (MEN) type 2. The MEN2 gene has been identified as the RET proto-oncogene. Mutations in the RET proto-oncogene are associated with the pathogenesis of MTC. Approximately 23-40% of sporadic MTCs (sMTCs) have a somatic RET codon 918 mutation within the catalytic core of the tyrosine kinase, which is a mutation found in over 98% of all MEN 2B cases as a germline mutation.METHODS: In order to elucidate the role of this mutation, we examined 40 sMTCs for the codon 918 mutation. Simultaneously, we looked for overexpression of the RET protein by means of immunohistochemistry with a newly developed RET antibody.RESULTS: In 8 of 40 tumors (20%), we were able to find a RET codon 918 mutation. Nine of 40 tumors (22.5%) showed immunoreactivity with the RET antibody.CONCLUSION: The presence of the somatic RET codon 918 mutations did not correlate with the presence of positive RET immunostaining.",
keywords = "Carcinoma, Medullary, Codon, Humans, Immunohistochemistry, Multiple Endocrine Neoplasia Type 2a, Mutation, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Proto-Oncogenes, Thyroid Neoplasms",
author = "M Bockhorn and A Frilling and V Kalinin and S Schr{\"o}der and Broelsch, {C E}",
year = "1999",
month = feb,
day = "1",
language = "English",
volume = "384",
pages = "60--4",
journal = "LANGENBECK ARCH SURG",
issn = "1435-2443",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma

AU - Bockhorn, M

AU - Frilling, A

AU - Kalinin, V

AU - Schröder, S

AU - Broelsch, C E

PY - 1999/2/1

Y1 - 1999/2/1

N2 - INTRODUCTION: Medullary thyroid carcinoma (MTC) occurs sporadically or as part of the inherited cancer syndrome, multiple endocrine neoplasia (MEN) type 2. The MEN2 gene has been identified as the RET proto-oncogene. Mutations in the RET proto-oncogene are associated with the pathogenesis of MTC. Approximately 23-40% of sporadic MTCs (sMTCs) have a somatic RET codon 918 mutation within the catalytic core of the tyrosine kinase, which is a mutation found in over 98% of all MEN 2B cases as a germline mutation.METHODS: In order to elucidate the role of this mutation, we examined 40 sMTCs for the codon 918 mutation. Simultaneously, we looked for overexpression of the RET protein by means of immunohistochemistry with a newly developed RET antibody.RESULTS: In 8 of 40 tumors (20%), we were able to find a RET codon 918 mutation. Nine of 40 tumors (22.5%) showed immunoreactivity with the RET antibody.CONCLUSION: The presence of the somatic RET codon 918 mutations did not correlate with the presence of positive RET immunostaining.

AB - INTRODUCTION: Medullary thyroid carcinoma (MTC) occurs sporadically or as part of the inherited cancer syndrome, multiple endocrine neoplasia (MEN) type 2. The MEN2 gene has been identified as the RET proto-oncogene. Mutations in the RET proto-oncogene are associated with the pathogenesis of MTC. Approximately 23-40% of sporadic MTCs (sMTCs) have a somatic RET codon 918 mutation within the catalytic core of the tyrosine kinase, which is a mutation found in over 98% of all MEN 2B cases as a germline mutation.METHODS: In order to elucidate the role of this mutation, we examined 40 sMTCs for the codon 918 mutation. Simultaneously, we looked for overexpression of the RET protein by means of immunohistochemistry with a newly developed RET antibody.RESULTS: In 8 of 40 tumors (20%), we were able to find a RET codon 918 mutation. Nine of 40 tumors (22.5%) showed immunoreactivity with the RET antibody.CONCLUSION: The presence of the somatic RET codon 918 mutations did not correlate with the presence of positive RET immunostaining.

KW - Carcinoma, Medullary

KW - Codon

KW - Humans

KW - Immunohistochemistry

KW - Multiple Endocrine Neoplasia Type 2a

KW - Mutation

KW - Protein-Tyrosine Kinases

KW - Proto-Oncogene Proteins

KW - Proto-Oncogenes

KW - Thyroid Neoplasms

M3 - SCORING: Journal article

C2 - 10367632

VL - 384

SP - 60

EP - 64

JO - LANGENBECK ARCH SURG

JF - LANGENBECK ARCH SURG

SN - 1435-2443

IS - 1

ER -